Due to its strong association with resistance to immune checkpoint inhibitors, hyperactive TGF-β signaling has been proposed as a potential biomarker for cancer treatment resistance, particularly in checkpoint inhibitor therapies [34]. Here, TGFB1 is linked to cancer.